Park Kimberly 4

What Happened

• Kimberly Park, a director of Corcept Therapeutics (CORT), was granted a derivative award of 12,500 shares on May 21, 2026. The award is reported at $0.00 per share (no cash purchase) and is a compensatory grant rather than an open-market trade.

Key Details

• Transaction date: 2026-05-21; Filing date: 2026-05-26 (filed 5 days after the transaction; Form 4 is typically due within 2 business days, so this appears late).
• Award: 12,500 shares listed as a derivative acquisition at $0.00 per share (total reported acquisition value $0).
• Vesting: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over one year, contingent on continued service.
• Shares owned after transaction: Not reported in this filing.
• Remarks: Power of attorney used to sign the form is on file with the SEC.

Context

• This was a compensation grant (an award), not a purchase or sale; it does not involve immediate cash outflow or an open-market trade. Because the award vests over 12 months, economic exposure depends on future vesting/exercise and any subsequent sales. Grants to directors are common as part of board compensation and should be interpreted as compensation-related, not a direct market endorsement.